Skip to Content
  • Previous Rank
    100
  • Revenues ($M)
    $81,581.00
  • Revenue Percent Change
    6.7%
  • Profits ($M)
    $15,297.00
  • Profits Percent Change
    1076.70%
  • Assets ($M)
    $152,954.00
  • Employees
    135,100

The 133-year-old health care conglomerate makes everything from Band-Aids and baby shampoo to contact lenses and hip implants, but its $40.7 billion pharmaceutical division is what drove the most revenue growth in 2018. The company’s cancer and immunology drugs sold especially well. J&J’s medical device division eked out sales growth despite divestitures, as did the company’s consumer business, which continues to see challenges in its recently relaunched baby care line. The company faces more than 13,000 lawsuits—and federal inquiries—over the safety of its talc-based baby powder. (J&J maintains the product is perfectly safe.)

Company Information

CEO
Alex Gorsky
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New Brunswick, N.J.
Websitehttps://www.jnj.com
Years on Global 500 List19
Employees135,100
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Johnson & Johnson Rank History

placeholder

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$81,581.006.7%
Profits ($M)$15,297.001076.70%
Assets ($M)$152,954.00-
Total Stockholder Equity ($M)$59,752.00-

Profit Ratios

Profit as % of Revenues18.8%
Profits as % of Assets10%
Profits as % of Stockholder Equity25.6%